#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

The an­ti-PD-1/L1 mar­ket has grown in­creas­ing­ly packed in re­cent years with a slate of late ad­di­tions look­ing to carve out mar­ket share. A Chi­nese com­peti­tor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER